The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...

NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and ...

LONDON – 13 November 2025 -- CHARM Therapeutics (“CHARM”, “The Company”), today announced the advancement of CHM-029, a next-generation pan-menin inhibitor designed to overcome resistance mutations, ...

Pediatric acute myeloid leukemia (AML) is one of the most common acute leukemias in children. While treatment outcomes have ...

– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML – – FLT3 mutations occur in approximately 30% of ...

University of Cincinnati Cancer Center experts will present abstracts at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Dec. 7-10 in San Diego. Trial finds AML drug is ...

Researchers from the University of Toronto (Canada) have presented a new high-resolution gene expression atlas that shows the normal differentiation process of hematopoietic cells at the American ...

- Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML - - FLT3 mutations occur in approximately 30% of ...